Abstract
Background Whereas accumulating studies on COVID-19 patients report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID-19 patients compares to those observed in hospitalized patients with other viral pneumonias such as influenza is unknown.
Objectives To assess the incidence of venous and arterial thrombotic complications in hospitalized influenza patients as opposed to that observed in hospitalized COVID-19 patients.
Methods Retrospective cohort study; we used data from Statistics Netherlands (study period: 2018) on thrombotic complications in hospitalized influenza patients. In parallel, we assessed the cumulative incidence of thrombotic complications – adjusted for competing risk of death - in patients with COVID-19 in three Dutch hospitals (February 24th - April 26th 2020).
Results Of the 13.217 hospitalized influenza patients, 437 (3.3%) were diagnosed with thrombotic complications, versus 66 (11%) of the 579 hospitalized COVID-19 patients. The 30-day cumulative incidence of any thrombotic complication in influenza was 11% (95%CI 9.4-12) versus 25% (95%CI 18-32) in COVID-19. For venous thrombotic complications (VTE) and arterial thrombotic complications alone, these numbers were respectively 3.6% (95%CI 2.7-4.6) and 7.5% (95%CI 6.3-8.8) in influenza versus 23% (95%CI 16-29) and 4.4% (95%CI 1.9-8.8) in COVID-19.
Conclusions The incidence of thrombotic complications in hospitalized influenza patients was lower than in hospitalized COVID-19 patients. This difference was mainly driven by a high risk of VTE complications in the COVID-19 patients admitted to ICU. Remarkably, influenza patients were more often diagnosed with arterial thrombotic complications.
Essentials
It is unknown how COVID-19 compares to patients with other virus infections regarding thrombosis.
Hospitalized patients with influenza and COVID-19 were evaluated and compared to each other.
30-day cumulative incidence of thrombosis was lower in influenza (11%) than in COVID-19 (25%).
Difference was mainly driven by a high risk of VTE in COVID-19 patients admitted to the ICU.
Competing Interest Statement
Frederikus Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi-Sankyo, MSD and Actelion, the Dutch Heart foundation, ZonMW Dutch Healthcare Fund and the Dutch Thrombosis association, all outside the submitted work. Menno Huisman reports grants from ZonMW Dutch Healthcare Fund, and grants and personal fees from Boehringer-Ingelheim, Pfizer-BMS, Bayer Health Care, Aspen, Daiichi-Sankyo, Leo Pharma, all outside the submitted work. The other authors having nothing to disclose.
Funding Statement
This study was funded by unrestricted grants of the participating hospitals. The steering committee, consisting of the authors, had final responsibility for the study design, oversight, and data verification and analyses. The sponsor was not involved in the study. All members of the steering committee contributed to the interpretation of the results, approved the final version of the manuscript, and vouch for the accuracy and completeness of the data reported. The corresponding author (MV Huisman) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The final decision to submit the manuscript was made by the corresponding author on behalf of all co-authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards of the LUMC for observational studies.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymous data on hospitalized COVID19 patients as collected in this study can be made available to others, on request to the corresponding author of this manuscript (MV Huisman). The request will be granted after approval of a methodologically sound proposal and a signed data sharing agreement is required. Data will be available after publication of the article and until five years following article publication. Unfortunately, data on hospitalized influenza patients cannot be shared with third parties as Statistics Netherlands does not permit this. No other relevant documents are available.
